|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBH1 |
Gene summary for FBH1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBH1 | Gene ID | 84893 |
| Gene name | F-box DNA helicase 1 | |
| Gene Alias | FBXO18 | |
| Cytomap | 10p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | B3KV95 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84893 | FBH1 | NAFLD1 | Human | Liver | NAFLD | 8.27e-08 | 6.13e-01 | -0.04 |
| 84893 | FBH1 | S014 | Human | Liver | HCC | 1.13e-18 | 6.25e-01 | 0.2254 |
| 84893 | FBH1 | S015 | Human | Liver | HCC | 1.98e-08 | 4.54e-01 | 0.2375 |
| 84893 | FBH1 | S016 | Human | Liver | HCC | 6.19e-13 | 5.05e-01 | 0.2243 |
| 84893 | FBH1 | S027 | Human | Liver | HCC | 8.29e-14 | 7.38e-01 | 0.2446 |
| 84893 | FBH1 | S028 | Human | Liver | HCC | 1.27e-15 | 6.32e-01 | 0.2503 |
| 84893 | FBH1 | S029 | Human | Liver | HCC | 7.32e-18 | 6.87e-01 | 0.2581 |
| 84893 | FBH1 | male-WTA | Human | Thyroid | PTC | 1.90e-14 | 2.20e-01 | 0.1037 |
| 84893 | FBH1 | PTC01 | Human | Thyroid | PTC | 2.66e-05 | 1.33e-01 | 0.1899 |
| 84893 | FBH1 | PTC03 | Human | Thyroid | PTC | 3.54e-03 | 1.57e-01 | 0.1784 |
| 84893 | FBH1 | PTC04 | Human | Thyroid | PTC | 2.48e-11 | 2.17e-01 | 0.1927 |
| 84893 | FBH1 | PTC05 | Human | Thyroid | PTC | 1.26e-11 | 3.66e-01 | 0.2065 |
| 84893 | FBH1 | PTC06 | Human | Thyroid | PTC | 3.17e-19 | 4.11e-01 | 0.2057 |
| 84893 | FBH1 | PTC07 | Human | Thyroid | PTC | 1.68e-15 | 2.85e-01 | 0.2044 |
| 84893 | FBH1 | ATC09 | Human | Thyroid | ATC | 1.77e-08 | 3.19e-01 | 0.2871 |
| 84893 | FBH1 | ATC11 | Human | Thyroid | ATC | 2.49e-06 | 4.38e-01 | 0.3386 |
| 84893 | FBH1 | ATC12 | Human | Thyroid | ATC | 2.48e-11 | 2.44e-01 | 0.34 |
| 84893 | FBH1 | ATC13 | Human | Thyroid | ATC | 3.11e-50 | 8.55e-01 | 0.34 |
| 84893 | FBH1 | ATC1 | Human | Thyroid | ATC | 1.52e-06 | 2.96e-01 | 0.2878 |
| 84893 | FBH1 | ATC2 | Human | Thyroid | ATC | 9.20e-14 | 7.18e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:00346556 | Liver | NAFLD | nucleobase-containing compound catabolic process | 80/1882 | 407/18723 | 3.07e-09 | 4.61e-07 | 80 |
| GO:0051053 | Liver | NAFLD | negative regulation of DNA metabolic process | 26/1882 | 125/18723 | 2.52e-04 | 4.12e-03 | 26 |
| GO:20012337 | Liver | NAFLD | regulation of apoptotic signaling pathway | 57/1882 | 356/18723 | 2.73e-04 | 4.41e-03 | 57 |
| GO:20012354 | Liver | NAFLD | positive regulation of apoptotic signaling pathway | 26/1882 | 126/18723 | 2.87e-04 | 4.57e-03 | 26 |
| GO:00510526 | Liver | NAFLD | regulation of DNA metabolic process | 56/1882 | 359/18723 | 5.95e-04 | 7.92e-03 | 56 |
| GO:00510987 | Liver | NAFLD | regulation of binding | 56/1882 | 363/18723 | 7.80e-04 | 9.77e-03 | 56 |
| GO:20012444 | Liver | NAFLD | positive regulation of intrinsic apoptotic signaling pathway | 14/1882 | 58/18723 | 1.48e-03 | 1.64e-02 | 14 |
| GO:20010206 | Liver | NAFLD | regulation of response to DNA damage stimulus | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
| GO:00971937 | Liver | NAFLD | intrinsic apoptotic signaling pathway | 44/1882 | 288/18723 | 3.24e-03 | 2.88e-02 | 44 |
| GO:00323922 | Liver | NAFLD | DNA geometric change | 18/1882 | 90/18723 | 3.34e-03 | 2.93e-02 | 18 |
| GO:20010224 | Liver | NAFLD | positive regulation of response to DNA damage stimulus | 20/1882 | 105/18723 | 3.71e-03 | 3.16e-02 | 20 |
| GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
| GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
| GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
| GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
| GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |